排序方式: 共有59条查询结果,搜索用时 18 毫秒
1.
2.
3.
AlHabib KF Hersi A Alsheikh-Ali AA Sulaiman K Alfaleh H Alsaif S Almahmeed W Asaad N Amin H Al-Motarreb A Al-Lawati J Al Suwaidi J;Gulf RACE- Investigators 《Angiology》2012,63(2):109-118
We assessed the prevalence, predictors, and in-hospital and long-term outcomes of conservative medical management for patients with non-ST-segment elevation acute coronary syndrome (NSTEACS) compared with percutaneous coronary intervention (PCI) and coronary artery bypass graft surgery (CABG). This prospective study conducted from October 2008 to June 2009 in 65 hospitals from 6 Arabian Gulf countries included 30-day and 1-year mortality follow-up for 3661 patients. Compared with conservative management group (2859 patients; 78.1%), the PCI group (638; 17.4%) had significantly better unadjusted and adjusted in-hospital (odds ratio [OR]: 0.40, 95% confidence interval [CI]: 0.17-0.97), 30-day (OR: 0.44, 95% CI: 0.24-0.76) and 1-year (OR: 0.58, 95% CI: 0.40-0.87) mortality rates. Comparison with the CABG group (164; 4.5%) yielded similar results with inclusion of patients scheduled for CABG after hospital discharge. Independent predictors of conservative medical management were mainly country of residence and history of prior CABG. 相似文献
5.
Worsening heart failure in ‘real‐world’ clinical practice: predictors and prognostic impact
下载免费PDF全文
![点击此处可从《European journal of heart failure》网站下载免费的PDF全文](/ch/ext_images/free.gif)
6.
Rationale and design of the AdaptResponse trial: a prospective randomized study of cardiac resynchronization therapy with preferential adaptive left ventricular‐only pacing
下载免费PDF全文
![点击此处可从《European journal of heart failure》网站下载免费的PDF全文](/ch/ext_images/free.gif)
Gerasimos Filippatos David Birnie Michael R. Gold Bart Gerritse Ahmad Hersi Sandra Jacobs Kengo Kusano Christophe Leclercq Wilfried Mullens Bruce L. Wilkoff 《European journal of heart failure》2017,19(7):950-957
The AdaptResponse trial is designed to test the hypothesis that preferential adaptive left ventricular‐only pacing with the AdaptivCRT® algorithm reduces the incidence of the combined endpoint of all‐cause mortality and intervention for heart failure (HF) decompensation, compared with conventional cardiac resynchronization therapy (CRT), among patients with a CRT indication, left bundle branch block (LBBB) and normal atrioventricular (AV) conduction. The AdaptResponse study is a prospective, randomized, controlled, single‐blinded, multicentre, clinical trial ( ClinicalTrials.gov Identifier: NCT02205359), conducted at up to 200 centres worldwide. Following enrolment and baseline assessment, eligible subjects will be implanted with a CRT system containing the AdaptivCRT algorithm, and randomized in a 1:1 fashion to either a treatment (‘AdaptivCRT’) or control (‘Conventional CRT’) group. The study is designed to observe a primary endpoint in 1100 patients (‘event‐driven’) and approximately 3000 patients will be randomized. The primary endpoint is the composite of all‐cause mortality and intervention for HF decompensation; secondary endpoints include all‐cause mortality, intervention for HF decompensation, clinical composite score (CCS) at 6 months, atrial fibrillation, quality of life measured by the Kansas City Cardiomyopathy Questionnaire (KCCQ), health outcome measured by the EQ‐5D instrument, all‐cause readmission after a HF admission, and cost‐effectiveness. The AdaptResponse clinical trial is powered to assess clinical endpoints and is expected to provide definitive evidence on the incremental utility of AdaptivCRT‐enhanced CRT systems. 相似文献
7.
8.
9.
Atrial fibrillation (AF) is the most common sustained tachyarrhythmia encountered in clinical practice. The management of
AF remains associated with many challenges that make its treatment a vexing problem. However, in recent years extraordinary
progress has been made in the understanding and management of AF. In general, antiarrhythmic drugs for rhythm control have
been disappointing. We have a better understanding of pharmacologic cardioversion and this has led to newer strategies, such
as intermittent therapy. Several studies have been completed comparing pharmacologic rhythm control with pharmacologic heart
rate control. There is also an emerging body of evidence concerning the value of adjunctive drug use for rhythm control using
drugs that would not usually be considered to be antiarrhythmic. Finally, antithrombotic therapy is an increasingly important
part of the medical management of AF. This article summarizes the results of many of the recent publications and their clinical
implications concerning management of this common rhythm disorder. 相似文献
10.
Hepatitis B genotypes: Relation to clinical outcome in patients with chronic hepatitis B in Saudi Arabia 总被引:4,自引:0,他引:4
Abdo AA Al-Jarallah BM Sanai FM Hersi AS Al-Swat K Azzam NA Al-Dukhayil M Al-Maarik A Al-Faleh FZ 《World journal of gastroenterology : WJG》2006,12(43):7019-7024
INTRODUCTION Hepatitis B virus (HBV) infection is a global health problem with over 350 million chronic carriers of the virus with the risk of developing chronic hepatitis, cirrhosis or hepatocellular carcinoma (HCC). HBV is a circular, partially double-s… 相似文献